Spots Global Cancer Trial Database for phase 1b
Every month we try and update this database with for phase 1b cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Dose-escalation Study to Evaluate the Safety and Tolerability of GX-I7 in Patients With Glioblastoma | NCT03619239 | Newly Diagnosed... | GX-I7 | 19 Years - | Genexine, Inc. | |
| A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL. | NCT02417285 | Lymphoma, Large... Lymphoma, Non-H... | Obinutuzumab CC-122 | 18 Years - | Celgene | |
| Effect of Different Doses of AMG 706 on the Gallbladder in Advanced Solid Tumors | NCT00448786 | Solid Tumors | AMG 706 AMG 706 AMG 706 | 18 Years - | Amgen | |
| QUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid Tumors | NCT00974896 | Advanced Malign... Advanced Solid ... Cancer Solid Tumors Tumors | AMG 479 | 18 Years - | NantCell, Inc. | |
| Safety and Efficacy of Donafenib in Patients With Advanced Hepatocellular Carcinoma | NCT02229071 | HCC | Donafenib(200mg... Donafenib(300mg... | 18 Years - 70 Years | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | |
| A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors. | NCT01441388 | Carcinoma, Rena... Glioblastoma Carcinoma, Hepa... | Crizotinib plus... Crizotinib plus... Crizotinib plus... Crizotinib plus... Crizotinib plus... Crizotinib plus... Crizotinib plus... | 18 Years - | Pfizer | |
| Study Of SU011248 In Combination With Docetaxel In Patients With Metastatic Breast Cancer | NCT00291577 | Breast Neoplasm... | Sunitinib (Sute... Taxotere | 18 Years - | Pfizer | |
| QUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid Tumors | NCT00974896 | Advanced Malign... Advanced Solid ... Cancer Solid Tumors Tumors | AMG 479 | 18 Years - | NantCell, Inc. | |
| Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer | NCT01010945 | Advanced Pancre... | erlotinib gemcitabine nab-paclitaxel | 18 Years - | Astellas Pharma Inc | |
| Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia | NCT01351935 | B Cell Non-Hodg... Chronic Lymphoc... Waldenstrom Mac... | AVL-292 | 18 Years - | Celgene | |
| Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia | NCT01351935 | B Cell Non-Hodg... Chronic Lymphoc... Waldenstrom Mac... | AVL-292 | 18 Years - | Celgene | |
| Clinical Study on the Safety and Tolerability of Macitentan in Combination With Dose-dense Temozolomide in Patients With Recurrent Glioblastoma | NCT01499251 | Glioblastoma | Phase 1 Dose Es... Phase 1b Ancillary Study | 18 Years - | Actelion | |
| Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer | NCT02270372 | Advanced Breast... Advanced Ovaria... | ONT-10, Varlilu... | 18 Years - | Seagen Inc. | |
| A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene | NCT02141828 | Leukemia Acute Myeloid L... Acute Lymphocyt... Acute Leukemias | EPZ-5676 | 3 Months - 18 Years | Ipsen | |
| A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | NCT06362369 | Advanced Cancer Advanced Solid ... Melanoma Metastasis Pleural Mesothe... Renal Cell Carc... MSI-High Mismatch Repair... Colorectal Canc... Hepatocellular ... Hepatocellular ... Renal Cell Canc... Kidney Cancer Skin Cancer Non Small Cell ... NSCLC Anaplastic Lymp... ALK Genomic Tum... | Alintegimod Ipilimumab Nivolumab | 18 Years - | 7 Hills Pharma, LLC | |
| Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects | NCT01323062 | Non Small Cell ... | Bavituximab | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Effect of Different Doses of AMG 706 on the Gallbladder in Advanced Solid Tumors | NCT00448786 | Solid Tumors | AMG 706 AMG 706 AMG 706 | 18 Years - | Amgen | |
| Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects | NCT01323062 | Non Small Cell ... | Bavituximab | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Dose-escalation Study to Evaluate the Safety and Tolerability of GX-I7 in Patients With Glioblastoma | NCT03619239 | Newly Diagnosed... | GX-I7 | 19 Years - | Genexine, Inc. | |
| E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck | NCT01332266 | Platinum-Resist... | E7050 Cetuximab | 18 Years - | Eisai Inc. | |
| Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin | NCT03043989 | Prostate Cancer | Docetaxel Cabazitaxel Clarithromycin | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Phase 1b Maintenance Therapy Study of ONT-10 in Patients With Solid Tumors | NCT01978964 | Solid Tumors | ONT-10 | 18 Years - 70 Years | Seagen Inc. | |
| Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer | NCT02270372 | Advanced Breast... Advanced Ovaria... | ONT-10, Varlilu... | 18 Years - | Seagen Inc. | |
| c-Met Second-Line Hepatocellular Carcinoma | NCT02115373 | Carcinoma, Hepa... | Tepotinib Tepotinib | 18 Years - | Merck KGaA, Darmstadt, Germany | |
| Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer | NCT04822298 | Non-small Cell ... NSCLC | AMG 160 | 18 Years - | Amgen | |
| Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC | NCT00633529 | Non-Small Cell ... | IMO-2055 | 18 Years - | EMD Serono | |
| Safety and Efficacy of Donafenib in Patients With Advanced Hepatocellular Carcinoma | NCT02229071 | HCC | Donafenib(200mg... Donafenib(300mg... | 18 Years - 70 Years | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | |
| Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin | NCT03043989 | Prostate Cancer | Docetaxel Cabazitaxel Clarithromycin | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC | NCT00633529 | Non-Small Cell ... | IMO-2055 | 18 Years - | EMD Serono |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
